Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
6681 results about "Anti tumour" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
Integration of costimulatory signaling domains within a tumor targeting chimeric antigen receptor (CAR), such as the IL13Rα2 specific IL13-zetakine (IL13ζ), enhances T cell-mediated responses against tumors even in the absence of expressed ligands for costimulatory receptors.
Owner:CITY OF HOPE
Cyclic single-chain trispecific antibody
The invention provides a cyclic single-chain trispecific antibody against human tumor. It comprises three parts. The first part is an anti-tumor Fab antibody, an anti-tumor single-domain antibody or an scFv. The second part is a reshaped Fab antibody against human CD3, a reshaped single-domain antibody against human CD3 or a reshaped scFv against human CD3. The third part is a reshaped Fab antibody against human CD28, a reshaped single-domain antibody against human CD28 or a reshaped scFv against human CD28. The present invention also offers the DNA sequence coding for this trispecific antibody, expression vectors containing this DNA sequence and host cells (E. coli) containing the vectors.
Owner:DONGGUAN HAOFA BIOTECH DEVAL +2
Bioactive Polymers
InactiveUS20080267903A1Strong specificityEnhanced interactionSynthetic polymeric active ingredientsAntineoplastic agentsDelivery vehicleActive agent
Various polymers, including cationic polyamine polymers and dendrimeric polymers, are shown to possess anti-proliferative activity, and may therefore be useful for treatment of disorders characterised by undesirable cellular proliferation such as neoplasms and tumours, inflammatory disorders (including autoimmune disorders), psoriasis and atherosclerosis. The polymers may be used alone as active agents, or as delivery vehicles for other therapeutic agents, such as drug molecules or nucleic acids for gene therapy. In such cases, the polymers' own intrinsic anti-tumour activity may complement the activity of the agent to be delivered.
Owner:UNIV COLLEGE OF LONDON
Epothilone derivatives and their use as antitumor agents
The invention relates to anti-tumour-effective compounds of formula (I), wherein the radicals have the meanings given in the description.
Owner:NOVARTIS AG
Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
ActiveUS20170096461A1High error rateIncrease in motilityNervous disorderAntibody mimetics/scaffoldsPeptideDrug
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Owner:IMMATICS BIOTECHNOLOGIES GMBH
Tumour-associated peptides binding to human leukocyte antigen (HLA) class i or ii molecules and related Anti-cancer vaccine
InactiveUS20090274714A1Organic active ingredientsPeptide/protein ingredientsHla class iiAdditive ingredient
The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to two novel peptide sequences derived from HLA class II molecules of human tumour cell lines, which can be used in vaccine compositions for eliciting anti-tumour immune responses.
Owner:IMMATICS BIOTECHNOLOGIES GMBH
Imidazothiazole derivatives
There is provided a novel compound that inhibits interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. The present invention provides an imidazothiazole derivative represented by the following formula (1) having various substituents that inhibits interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity:
wherein R1, R2, R3, R4, and R5 in the formula (1) each has the same meaning as defined in the specification.
Owner:DAIICHI SANKYO CO LTD
Structure and use of 5' phosphate oligonucleotides
Oligonucleotides bearing free, uncapped 5′ phosphate group(s) are recognized by RIG-I, leading to the induction of type I IFN, IL-18 and IL-1β production. Bacterial RNA also induces type I IFN production. 5′ phosphate oligonucleotides and bacterial RNA can be used for inducing an anti-viral response or an anti-bacterial response, in particular, type I IFN and / or IL-18 and / or IL-1β production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies and immunosuppression. Single-stranded 5′ triphosphate RNA can be used for inducing an anti-viral response, an anti-bacterial response, or an anti-tumor response, in particular, type I IFN and / or IL-18 and / or IL-1β production, in a target cell-specific manner.
Owner:UNIVERSITY OF BONN
Cobalamin conjugates for anti-tumor therapy
The present invention provides a cobalamin-drug conjugate suitable for the treatment of tumor related diseases. Cobalamin is indirectly covalently bound to an anti-tumor drug via a cleavable linker and one or more optional spacers. Cobalamin is covalently bound to a first spacer or the cleavable linker via the 5′-OH of the cobalamin ribose ring. The drug is bound to a second spacer of the cleavable linker via an existing or added functional group on the drug. After administration, the conjugate forms a complex with transcobalamin (any of its isoforms). The complex then binds to a receptor on a cell membrane and is taken up into the cell. Once in the cell, an intracellular enzyme cleaves the conjugate thereby releasing the drug. Depending upon the structure of the conjugate, a particular class or type of intracellular enzyme affects the cleavage. Due to the high demand for cobalamin in growing cells, tumor cells typically take up a higher percentage of the conjugate than do normal non-growing cells. The conjugate of the invention advantageously provides a reduced systemic toxicity and enhanced efficacy as compared to a corresponding free drug.
Owner:INFLABLOC PHARMA
Novel immunogenic epitope for immunotherapy
ActiveUS20090136528A1Organic active ingredientsPeptide/protein ingredientsAdditive ingredientWilms' tumor
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses.
Owner:IMMATICS BIOTECHNOLOGIES GMBH
FAP-activated anti-tumor compounds
The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAPalpha), said prodrug having a cleavage site which is recognised by FAPalpha, and said drug being cytotoxic or cytostatic under physiological conditions.
Owner:BOEHRINGER INGELHEIM PHARM KG
Synthesis of FR901464 and analogs with antitumor activity
The present invention provides novel analogs of FR901464, as well as an improved methodology for preparing FR901464 and its analogs. These compounds display an anti-cancer activity and are candidates for therapies against a number of disease states associated with dysfunctional RNA splicing.
Owner:UNIVERSITY OF PITTSBURGH
Pyrimidine derivatives containing semicarbazide and terminal alkyne structural units, and preparation methods and applications of pyrimidine derivatives
ActiveCN104119280AHigh activityMild reaction conditionsOrganic active ingredientsOrganic chemistryAlkynePharmaceutical Substances
The invention belongs to the field of medicinal chemistry, and discloses pyrimidine compounds containing semicarbazide and terminal alkyne structural units, and preparation methods and applications of the pyrimidine compounds in preparation of antitumor drugs by taking lysine specific demethylase 1 (hereafter referred to as LSD1) as a target. A pyrimidine active fragment is built by adopting a three-component one-pot method, and then the target compounds are prepared by substitution, chlorination and ammonification reaction. The general formulas of the compounds are as shown in the formula I in the specification. An in vitro anti-tumor activity experiment and an LSD1 inhibition activity experiment prove that the compounds have obvious inhibiting and killing action on a plurality of tumor cells by inhibiting the activity of the LSD1, can be used as lead compounds for further development, and are applied to preparation of the antitumor drugs.
Owner:ZHENGZHOU UNIV
Immunocyte culture medium, and culture method and application of immunocytes
InactiveCN104818248AHigh speedExtended passage timesBlood/immune system cellsAntiendomysial antibodiesCell culture media
The invention discloses an immunocyte culture medium, and a culture method and application of immunocytes. The immunocyte culture medium is composed of one or more selected from the group consisting of amino acids, vitamins, salts, lipids or polypeptide, and one or more selected from the group consisting of cytokines or antibodies; the immunocyte culture medium can quickly amplify different types of immunocytes, enables the amplification speed of the immunocytes to be increased by 3 to 5 times than the amplification speed of the immunocytes cultured with a conventional culture medium, and prolongs passage times; meanwhile, the immunocytes cultured by the immunocyte culture medium provided by the invention can maintain good immunocyte functions and exert effects including, but not limited to, anti-cancer effect and anti-aging effect, so the immunocytes have good application prospects.
Owner:BIOTOWNTEK CO LTD
Anaerobic bacterium as a drug for cancer gene therapy
InactiveUS20050025745A1Efficient deliveryEffective gene therapyBiocideBacteriaAbnormal tissue growthBifidobacterium
The present invention provides a bacterium belonging to the genus Bifidobacterium, by which DNA coding for a protein having an antitumor activity or DNA coding for a protein having the activity of converting a precursor of an antitumor substance into the antitumor substance is delivered to tumor tissues specifically under anaerobic conditions thereby expressing the protein encoded by the DNA, as well as a pharmaceutical composition comprising said anaerobic bacterium.
Owner:ANAEROPHARMA SCI
N-substituted benzothiazolyl-1-substituted phenyl-0, 0-dialkyl-alpha-amino phosphonate ester derivatives preparation and application
The present invention discloses a medicine with actions of resisting plant virus and resisting tumor-N-substituted benzothiazolyl-1-substituted phenyl-0.0-dialkyl-alpha- aminophosphonates derivative, its preparation method and biological activity. Said invention also provides its structure formula, and also provides its extensive application for inhibiting tobacco mosaic virus (TMV) activity and inhibiting activity of human body prostatic cancer cell PC3 and others.
Owner:GAUNGXI TIANYUAN BIOCHEM
CD47 and PD-L1 targeting bifunctional fusion protein
ActiveCN107459578AImprove targetingHigh activityPolypeptide with localisation/targeting motifAntibody mimetics/scaffoldsDisulfide bondingBlood safety
The invention relates to a CD47 and PD-L1 targeting bifunctional fusion protein, belongs to the field of biomedicine, and solves the problems that anti-PD-1 / PD-L1 treatment is poor in a low-immunogenicity tumor treatment effect and anti-CD47 treatment is poor in a targeting ability. The fusion protein is composed of a CD47 binding part and a PD-L1 binding part which are linked by a disulfide bond, can block the binding of CD47 and SIRPalpha, can block the binding of PD-L1 and PD-1, can achieve the effects of activating macrophages to phagocytize tumor cells and promoting antigen presentation in natural immunity, can achieve an effect of promoting the activation of tumor specific T cells in acquired immunity, and has lower blood toxicity; and as compared with the single use of anti-PD-L1 or anti-CD47 for treatment, the fusion protein has better antitumor curative effects and blood safety.
Owner:TAIZHOU MABTECH PHARM CO LTD
Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules
InactiveUS20080206216A1Organic active ingredientsPeptide/protein ingredientsHla class iiAdditive ingredient
The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
Owner:IMMATICS BIOTECHNOLOGIES GMBH
Tumor precision T cell containing efficient killing starting mechanism and application of tumor precision T cell
ActiveCN105331586AActivate proliferationActivate growthImmunoglobulins against cell receptors/antigens/surface-determinantsMammal material medical ingredientsAntigen receptorsT lymphocyte
The invention belongs to the fields of immunology and cell biology, and relates to a tumor precision T cell containing an efficient killing starting mechanism and an application of the tumor precision T cell, in particular to a CAR (chimeric antigen receptor) having moderate-affinity binding characteristic with a broad-spectrum expression membrane antigen on the tumor cell surface as well as a new-generation tumor precision T cell, namely, Baize T. T cell activation is started rapidly under the action of the CAR having the moderate-affinity binding characteristic, an activation signal of the CAR is superposed with a TCR (T cell receptor) signal with tumor antigen natural recognition capacity in a CTL (tumor-specific cytotoxic T lymphocyte), the CTL is activated to proliferate and grow in a tumor microenvironment, and a tumor cell is killed preciously by the tumor-antigen-specific TCR. The tumor precision T cell has broad anti-tumor application prospect.
Owner:SHANGHAI CELL THERAPY RES INST +2
Mhc multimers, methods for their generation, labeling and use
The present invention describes novel methods to generate MHC multimers and methods to improve existing and new MHC multimers. The invention also describes improved methods for the use of MHC multimers in analysis of T-cells in samples including diagnostic and prognostic methods. Furthermore the use of MHC multimers in therapy are described, e.g. anti-tumour and anti-virus therapy, including isolation of antigen specific T-cells capable of inactivation or elimination of undesirable targeT-cells or isolation of specific T-cells capable of regulation of other immune cells.
Owner:AGILENT TECH INC
Preparation of functional area of sea purse blood vessel growth inhibition factor 1 and use of the functional area of sea purse blood vessel growth inhibition factor 1 in medicaments for preventing and curing tumors
InactiveCN101724631AStrong specificityHigh expressionPeptide/protein ingredientsFermentationAbnormal tissue growthAcute toxicity testing
The invention relates to the preparation of a functional area of a sea purse blood vessel growth inhibition factor 1 and the use of the functional area of the sea purse blood vessel growth inhibition factor 1 in medicaments for preventing and curing tumors. In the invention, a gene engineering technique is used to realize the cloning, expression and recombination of the sea purse blood vessel growth inhibition factor 1; the recombinant functional fragment of the sea purse blood vessel growth inhibition factor 1 has the bioactivities for resisting the growth of blood vessels, tumor growth, tumor transplantation, acute toxicity tests and stability tests; and the functional area of the sea purse blood vessel growth inhibition factor 1 can be mixed with or dissolved in pharmaceutically acceptable carriers to prepare the medicaments for curing various tumors. The functional area of the sea purse blood vessel growth inhibition factor 1 has high action specificity, has the characteristics of easy expression, low degradation rate and the like of gene engineering medicaments and has the effects of inhibiting blood vessel growth, tumor growth and tumor transplantation; the provided gene engineering technique can realize the industrial production of the functional area of the sea purse blood vessel growth inhibition factor 1; and the functional area of the sea purse blood vessel growth inhibition factor 1 prepared by the gene engineering technique can be used in the preparation of medicaments for inhibiting blood vessel growth and preventing and curing tumors.
Owner:GUANGDONG OCEAN UNIVERSITY
Method for assay on the effect of vascularization inhibitor
ActiveUS20100092490A1Improve anti-tumor effectBiocideBiological material analysisAngiogenesis growth factorWilms' tumor
The present invention provides a method of predicting the antitumor effect of an angiogenesis inhibitor. It is possible to predict the antitumor effect of an angiogenesis inhibitor by evaluating the EGF dependency of a tumor cell for proliferation and / or survival and using the EGF dependency as an indicator. Since the antitumor effect of an angiogenesis inhibitor correlates with the EGF dependency of a tumor cell for proliferation and / or survival, the angiogenesis inhibitors is capable of producing excellent antitumor effect when combined with a substance having EGF inhibitory activity.
Owner:EISIA R&D MANAGEMENT CO LTD
Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins
InactiveUS20070026076A1Increase the number ofEasy to demonstratePowder deliveryVirusesDendritic cellVaccine Potency
T cell immune responses are enhanced by presentation of antigen to CD8+ T cells using a chimeric nucleic acid immunogen or vaccine that links DNA encoding an antigen with DNA encoding a polypeptide that targets or translocates the antigenic polypeptide to which it is fused (immunogenicity-potentiating polypeptides or “IPP”). By inhibiting apoptosis in the vicinity of a T cell responses to such a nucleic acid immunogen, even more potent immune responses are attained. The present strategy prolongs the survival of DNA-transduced cells, including dendritic cells (DCs), thereby enhancing the priming of antigen-specific T cells and increase potency. Co-delivery of DNA encoding an inhibitor of apoptosis, including (a) BCL-xL, (b) BCL-2, (c) XIAP, (d) dominant negative caspase-9, or (e) dominant negative caspase-8, or (f) serine protease inhibitor 6 (SPI-6) which inhibits granzyme B, with DNA encoding an antigen, prolongs the survival of transduced DCs and results in significant enhancement of antigenspecific T cell immune responses that provide potent antitumor effects. Thus, co-administration of a DNA vaccine encoding antigen linked to an IPP along with one or more DNA constructs encoding an anti-apoptotic protein provides a novel way to enhance vaccine potency.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Triterpene compositions and methods for use thereof
The invention provides novel saponin mixtures and compounds which are isolated from the species Acacia victoriae and methods for their use. These compounds may contain a triterpene moiety, such as acacic or oleanolic acid, to which oligosaccharides and monoterpenoid moieties are attached. The mixtures and compounds have properties related to the regulation of apoptosis and cytotoxicity of cells and exhibit potent anti-tumor effects against a variety of tumor cells.
Owner:RES DEVMENT FOUND
Preparation and application of exosome secreted by human derived blood or mesenchymal stem cell
InactiveCN103767985AAvoid blocking, not easily absorbed by cellsProtection stabilityCosmetic preparationsSenses disorderStem cell cultureSomatic cell
The invention discloses preparation and application of exosome secreted by human derived blood or mesenchymal stem cell. The preparation process of exosome comprises: extracting mesenchymal stem cells from health-human body blood or a stem cell culture supernatant, performing in-vitro culture and amplification, and utilizing means such as low-temperature separation, purification and the like to prepare high-purity high-bioactivity exosome. The blood or mesenchymal stem cell secreted exosome is added into medicines, health-care products and cosmetics according to ratios for developing of products with bioactivity, is capable of effectively regulating and controlling body cell signal transduction, activating cell regeneration, enhancing health cell proliferation and differentiation capacity, further regulating physiologic restoration or removing damaged, pathologic and aged cells of a body, fundamentally changing body physiologic functions, and helping to generate anti-tumor treatment effect by adjusting cellular immunity. The blood or mesenchymal stem cell secreted exosome is applicable to fields of medical science, health care and beauty treatment, and has wide application prospect.
Owner:珠海霍普金斯医药研究院股份有限公司
Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
ActiveUS20170035807A1High error rateOrganic active ingredientsPeptide/protein ingredientsReceptorOncology
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Owner:IMMATICS BIOTECHNOLOGIES GMBH
FAP-activated anti-tumor compounds
InactiveUS20020155565A1Sugar derivativesPeptide/protein ingredientsAbnormal tissue growthCytotoxicity
The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAPalpha), said prodrug having a cleavage site which is recognized by FAPalpha, and said drug being cytotoxic or cytostatic under physiological conditions, wherein said prodrug comprises an oligomeric part comprising at least two amino carboxylic residues, and a cytotoxic or cytostatic part, wherein the C-terminal amino carboxylic residue of the oligomeric part is an acyclic amino acid, the nitrogen atom of the amino function thereof is attached to a substituent being different from a hydrogen atom, and the C-terminal carboxy function thereof is linked to the cytotoxic or cytostatic part by an amide bond.
Owner:BOEHRINGER INGELHEIM PHARM KG
Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof
The present invention provides a compound of general formula 5, useful as potential antitumour agents against human cancer cell lines. The present invention further provides a process for the preparation of pyrrolo[2,1-c][1,4]benzodiazepine hybrids of general formula 5wherein, X1, X2, X3 is selected from H or Cl or CH3, Y is selected from O or NH, Z is selected from C═O or CH2 and n=1 to 4.![Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof](https://images-eureka.patsnap.com/patent_img/4cad00c5-7d16-4deb-8b56-f55326f6d430/US07528128-20090505-D00001.png "Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof")
![Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof](https://images-eureka.patsnap.com/patent_img/4cad00c5-7d16-4deb-8b56-f55326f6d430/US07528128-20090505-C00001.png "Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof")
![Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof](https://images-eureka.patsnap.com/patent_img/4cad00c5-7d16-4deb-8b56-f55326f6d430/US07528128-20090505-C00002.png "Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof")
Owner:COUNCIL OF SCI & IND RES
Sustained-release blood vessel embolic gel used for treating tumor, and preparation method thereof
ActiveCN102988274AEasy to injectNot easy to refluxPeptide/protein ingredientsDigestive systemEndovascular treatmentBlood vessel
The invention provides a sustained-release temperature-sensitive blood vessel embolic gel used for treating tumor. The sustained-release blood vessel embolic gel is prepared by entrapping a medicine by using a pharmaceutically acceptable carrier. The medicine is an anti-tumor medicine, and the pharmaceutically acceptable carrier comprises a gel prepared from poloxamer polymer, polyvinyl pyrrolidone, and the like or a composition thereof. The polymer material accounts for 5-65% of a gel mass. The particle size of the gel is in a range of 10nm to 150mum. The embolic agent is liquid gel under normal temperature, and can be used for direct injection through catheter. After injection into body, with the increase of temperature, the liquid gel is rapidly solidified into gel. Also, according to requirements, different medicines can be entrapped, and embolism and medication dual effect can be achieved through local sustained-release. Therefore, the gel provided by the invention can be used as an embolic agent for endovascular treatment, and can be used in various benign and malignant tumor transcatheter arterial chemoembolizations. The preparation method provided by the invention is simple, and is suitable for industrialized productions.
Owner:江苏申命医疗科技有限公司
Dioxygen piperazidine compounds and preparation method and usage thereof
The invention relates to preparation methods and uses of two dioxypiperazine compounds. The invention adopts aspergillus effuses H1-1 from root mud of Fujian mangrove forest to product novel structural dioxypiperazine compounds. Tests prove that: the compounds can be used as cellular breeding depressant or anti-tumor agent.
Owner:OCEAN UNIV OF CHINA +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap